Share on StockTwits

Abaxis (NASDAQ:ABAX) Director Henk Evenhuis sold 4,000 shares of the company’s stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $44.06, for a total transaction of $176,240.00. Following the transaction, the director now directly owns 10,400 shares in the company, valued at approximately $458,224. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Shares of Abaxis (NASDAQ:ABAX) traded down 0.41% on Thursday, hitting $43.49. 77,884 shares of the company’s stock traded hands. Abaxis has a 1-year low of $32.11 and a 1-year high of $51.84. The stock’s 50-day moving average is $39.89 and its 200-day moving average is $38.66. The company has a market cap of $968.6 million and a P/E ratio of 69.32.

Abaxis (NASDAQ:ABAX) last released its earnings data on Thursday, April 24th. The company reported $0.17 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.19 by $0.02. The company had revenue of $42.04 million for the quarter, compared to the consensus estimate of $45.74 million. During the same quarter in the prior year, the company posted $0.30 earnings per share. The company’s quarterly revenue was down 15.8% on a year-over-year basis. Analysts expect that Abaxis will post $0.91 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which is scheduled for Tuesday, June 17th. Stockholders of record on Tuesday, June 3rd will be paid a dividend of $0.10 per share. This represents a $0.40 annualized dividend and a dividend yield of 0.92%. The ex-dividend date is Friday, May 30th.

ABAX has been the subject of a number of recent research reports. Analysts at Canaccord Genuity raised their price target on shares of Abaxis from $34.00 to $39.00 in a research note on Wednesday. Separately, analysts at Feltl & Co. upgraded shares of Abaxis from a “sell” rating to a “hold” rating in a research note on Friday, April 25th. Finally, analysts at Zacks reiterated an “underperform” rating on shares of Abaxis in a research note on Wednesday, March 12th. They now have a $35.00 price target on the stock. Two analysts have rated the stock with a sell rating and two have given a hold rating to the company. Abaxis has an average rating of “Hold” and a consensus target price of $36.75.

Abaxis, Inc (NASDAQ:ABAX) develops, manufactures, markets and sells blood analysis systems for use in the human or veterinary patient-care setting to provide clinicians with rapid blood constituent measurements.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.